Nearly 25% of eyes with advanced age-related macular degeneration (AMD) would be eligible for intravitreal pegcetacoplan therapy, the first intravitreal anti-C3 agent, according to a study published in the Journal of Clinical Medicine. Alaa Din Abdin, MD, and colleagues examined the incidence of geographic atrophy (GA) in advanced AMD and the percentage of eyes that would be eligible for treatment with pegcetacoplan. They conducted a retrospective, cross-sectional study that included patients with AMD (n=2,033 eyes from n=1,027 patients), with eyes categorized by AMD stages. Based on foveal involvement, the research team separated eyes with GA into two groups. To identify predictive factors for foveal involvement, the study likened baseline factors between eyes with foveal GA (FGA) and those with non-foveal GA (NFGA). Results showed GA [932 (77%) FGA and 272 (23%) NFGA] present in 60% of eyes, while 125 eyes (27.4% from eyes with advanced dry AMD) met the indication criteria for pegcetacoplan treatment. “Foveal involvement of GA in advanced AMD seems to be more likely in neovascular AMD than in dry AMD,” the study authors wrote.
